( NASDAQ-NMS:ANTH )

News from anthera pharmaceuticals A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Feb 07, 2013, 17:29 ET Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) a biopharmaceutical company developing drugs to treat serious diseases associated with...


Feb 05, 2013, 08:30 ET Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that Senior Vice President of Product Development Georgina Kilfoil has...


Jan 30, 2013, 09:48 ET Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that it has completed the previously announced underwritten public offering...


Jan 25, 2013, 08:57 ET Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the pricing of an underwritten public offering of 60,606,061 shares of its...


Jan 24, 2013, 16:01 ET Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that it intends to offer and sell shares of its common stock in an underwritten...


Nov 28, 2012, 08:00 ET Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with...


Nov 20, 2012, 17:00 ET Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation...


Nov 13, 2012, 17:17 ET Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation...


Nov 01, 2012, 08:00 ET Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with...


Oct 24, 2012, 17:00 ET Anthera Pharmaceuticals Reports 2012 Third Quarter Financial Results And Provides Clinical Progress Update

Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended September 30, 2012....


Oct 18, 2012, 17:00 ET Anthera Announces Third Quarter 2012 Financial Report and Conference Call

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation...


Sep 17, 2012, 08:00 ET Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation...


Aug 07, 2012, 16:15 ET Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update

Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended June 30, 2012....


Aug 01, 2012, 14:00 ET Anthera to Report Second Quarter 2012 Financial Results

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with...


Jul 24, 2012, 16:15 ET Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it has completed the previously announced underwritten public offering of...


Jul 19, 2012, 09:16 ET Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the pricing of an underwritten public offering of 33 million shares of its...


Jul 18, 2012, 16:22 ET Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it intends to offer and sell shares of its common stock in an...


Jul 16, 2012, 13:26 ET Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation...


Jul 09, 2012, 17:02 ET Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with...


Jun 27, 2012, 17:40 ET Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod

 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with...